基因型指导的口服P2Y12抑制剂在直接PCI中的策略
该随机、开放标签、评估者盲法试验纳入2488例接受直接PCI并植入支架的患者,1:1分为基因型指导组(早期CYP2C19基因检测,功能缺失等位基因携带者用替格瑞洛或普拉格雷,非携带者用氯吡格雷)和标准治疗组(替格瑞洛或普拉格雷),疗程12个月。主要复合终点(全因死亡、心肌梗死、明确支架血栓、卒中或PLATO标准大出血)12个月发生率基因型指导组5.1% vs 标准治疗组5.9%(绝对差-0.7个百分点,95%CI -2.0至0.7,非劣效P<0.001)。主要出血终点(PLATO大或小出血)基因型指导组9.8% vs 标准治疗组12.5%(HR 0.78,95%CI 0.61-0.98,P=0.04)。结论认为基因型指导策略在血栓事件上非劣于标准治疗且出血发生率更低。
要点
- 直接PCI支架植入患者中,CYP2C19基因型指导组12个月主要复合终点5.1% vs 标准治疗组5.9%,绝对差-0.7个百分点(95%CI -2.0至0.7),达到非劣效(界值2个百分点)。
- 基因型指导组PLATO大或小出血12个月发生率9.8% vs 标准治疗组12.5%,HR 0.78(95%CI 0.61-0.98),P=0.04。
- 基因型指导组中CYP2C19*2或*3功能缺失等位基因携带者接受替格瑞洛或普拉格雷,非携带者接受氯吡格雷。
- 标准治疗组接受替格瑞洛或普拉格雷,疗程均为12个月。
- 该策略在直接PCI人群中非劣于标准治疗且出血更少,支持早期基因检测指导P2Y12抑制剂选择。
适用人群与场景
- 接受直接PCI并植入支架的患者,随机分组后治疗12个月。
处置流程与药物剂量
- 基因型指导组:基于早期CYP2C19基因检测,CYP2C19*2或*3功能缺失等位基因携带者接受替格瑞洛或普拉格雷,非携带者接受氯吡格雷,疗程12个月。
- 标准治疗组:接受替格瑞洛或普拉格雷,疗程12个月。
研究设计与关键结果
- 随机、开放标签、评估者盲法试验,纳入2488例直接PCI并植入支架患者,基因型指导组1242例,标准治疗组1246例。
- 主要复合终点(全因死亡、心肌梗死、明确支架血栓、卒中或PLATO标准大出血)12个月:基因型指导组63例(5.1%) vs 标准治疗组73例(5.9%),绝对差-0.7个百分点(95%CI -2.0至0.7),非劣效P<0.001(非劣效界值2个百分点)。
- 主要出血终点(PLATO大或小出血)12个月:基因型指导组122例(9.8%) vs 标准治疗组156例(12.5%),HR 0.78(95%CI 0.61-0.98),P=0.04。
证据类型、等级与局限
- 证据类型:随机、开放标签、评估者盲法试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在直接PCI患者中,CYP2C19基因型指导选择口服P2Y12抑制剂治疗在12个月血栓事件上非劣于替格瑞洛或普拉格雷标准治疗,且出血发生率更低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: It is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors.
METHODS: We conducted a randomized, open-label, assessor-blinded trial in which patients undergoing primary PCI with stent implantation were assigned in a 1:1 ratio to receive either a P2Y12 inhibitor on the basis of early CYP2C19 genetic testing (genotype-guided group) or standard treatment with either ticagrelor or prasugrel (standard-treatment group) for 12 months. In the genotype-guided group, carriers of CYP2C19*2 or CYP2C19*3 loss-of-function alleles received ticagrelor or prasugrel, and noncarriers received clopidogrel. The two primary outcomes were net adverse clinical events - defined as death from any cause, myocardial infarction, definite stent thrombosis, stroke, or major bleeding defined according to Platelet Inhibition and Patient Outcomes (PLATO) criteria - at 12 months (primary combined outcome; tested for noninferiority, with a noninferiority margin of 2 percentage points for the absolute difference) and PLATO major or minor bleeding at 12 months (primary bleeding outcome).
RESULTS: For the primary analysis, 2488 patients were included: 1242 in the genotype-guided group and 1246 in the standard-treatment group. The primary combined outcome occurred in 63 patients (5.1%) in the genotype-guided group and in 73 patients (5.9%) in the standard-treatment group (absolute difference, -0.7 percentage points; 95% confidence interval [CI], -2.0 to 0.7; P<0.001 for noninferiority). The primary bleeding outcome occurred in 122 patients (9.8%) in the genotype-guided group and in 156 patients (12.5%) in the standard-treatment group (hazard ratio, 0.78; 95% CI, 0.61 to 0.98; P = 0.04).
CONCLUSIONS: In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy for selection of oral P2Y12 inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding. (Funded by the Netherlands Organization for Health Research and Development; POPular Genetics ClinicalTrials.gov number, NCT01761786; Netherlands Trial Register number, NL2872.).
参考来源
- Claassens DMF, Vos GJA, Bergmeijer TO, et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med. 2019. PMID: 31479209. doi:10.1056/NEJMoa1907096
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。